All In Biotech

Drug Trial Radar · NCT06352138

Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients

Phase III, Multicentre, Double-blind, Randomised, Parallel, Equivalence Clinical Trial to Assess Efficacy, Safety of Megalabs® Recombinant i/v Human Erythropoietin Compared to Epogen® in Anaemia in Patients With Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Jul 2025

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
MegalabsIndustry
Sponsor type
Industry
First posted
Apr 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III, multicentre, double-blind, randomised, parallel, equivalence clinical trial to determine the efficacy, safety and immunogenicity of Megalabs® recombinant human alfa epoetin for intravenous use, compared to Epogen®, in the treatment of anaemia in participants with chronic renal disease, dependent on haemodialysis

Conditions

  • Anemia of Chronic Kidney Disease

Interventions

  • Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration.Biological

    comparison vs the reference product to demonstrate biological similarity

  • Active comparator: European Union licenced epoetin alfaBiological

    comparison vs. the test product to demonstrate biological similarity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Absolute Change in Hemoglobin LevelsTime frame: 18 months
  2. Change in Mean Hb LevelTime frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Megalabs

    Colonia Nicolich, Departamento de Canelones, Uruguay

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.